The ECP group showed a positive trend to a higher estimated glomerular filtration rate (eGFR) at 3 months (53 ± 11 vs. 47.1 ± 9; P = 0.17) and was statistically significant at 6 months (67.5 ± 10 vs. 53.6 ± 3; P = 0.03, Wilcoxon test).
However, improvement in quality of life measured by different scores, including SKINDEX, SF-36 or FACT, did not reach statistical significance. 220 It is intriguing to note that ECP has also been shown to be effective in erythroderma of other origin, such as red man syndrome, 228 , 229 erythrodermic pityriasis rubra pilaris 230 or photoaccentuated erythroderma associated with CD4 + T-lymphocytopenia. 231 ECP has also been found to improve